Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 209

    Novartis abandons effort for U.S. approval of biosimilar rituximab

    Novartis abandons effort for U.S. approval of biosimilar rituximab

    Medical Dialogues Bureau3 Nov 2018 9:10 AM IST
    According to analysts, Rituxan, a monoclonal antibody used in non-Hodgkin's lymphoma and rheumatoid arthritis, had more than $4 billion in sales in...
    Zydus Cadila gets USFDA Approval for Vardenafil Hydrochloride Tablets

    Zydus Cadila gets USFDA Approval for Vardenafil Hydrochloride Tablets

    Medical Dialogues Bureau2 Nov 2018 2:59 PM IST
    Ahmedabad: Zydus Cadila has launched Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg in the US market upon receiving the final...
    Strides Pharma Science to get Rs 147 Crore funding for consumer healthcare business

    Strides Pharma Science to get Rs 147 Crore funding for consumer healthcare business

    Medical Dialogues Bureau2 Nov 2018 11:57 AM IST
    The agreement also envisages Strides Consumer Pvt Ltd to become a fully owned subsidiary of Strides Global Consumer Healthcare Ltd at a later date,...
    Glenmark launches hair loss treatment Nourkrin in Russia

    Glenmark launches hair loss treatment Nourkrin in Russia

    Medical Dialogues Bureau2 Nov 2018 9:00 AM IST
    New Delhi: Glenmark Pharmaceuticals has recently announced the launch of Nourkrin, used to treat hair loss, in the Russian market.The product catering...
    Aurobindo Pharma Issues Voluntary Recall of Irbesartan Drug: FDA

    Aurobindo Pharma Issues Voluntary Recall of Irbesartan Drug: FDA

    Medical Dialogues Bureau1 Nov 2018 10:15 AM IST
    New Delhi: Aurobindo Pharma Limited is voluntarily recalling 22 Batches of the drug substance Irbesartan due to the presence of an impurity,...
    FDC gets 8 observation from USFDA for Waluj plant

    FDC gets 8 observation from USFDA for Waluj plant

    Medical Dialogues Bureau1 Nov 2018 10:02 AM IST
    New Delhi: Drug firm FDC has received establishment inspection report (EIR) from the US health regulator for its Waluj plant. The company said it had...
    Dr Reddys Labs launches Atomoxetine Capsules in US Market

    Dr Reddy's Labs launches Atomoxetine Capsules in US Market

    Medical Dialogues Bureau1 Nov 2018 9:20 AM IST
    Hyderabad: Dr. Reddy’s Laboratories Ltd. has recently announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of...
    Takeda hikes annual profit forecast by a third after second-quarter profit jump

    Takeda hikes annual profit forecast by a third after second-quarter profit jump

    Medical Dialogues Bureau1 Nov 2018 9:05 AM IST
    TOKYO: Japan's Takeda Pharmaceutical Co Ltd has boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong...
    Merck India Charitable Trust Scholarship program, launched in Bengaluru

    Merck India Charitable Trust Scholarship program, launched in Bengaluru

    Medical Dialogues Bureau1 Nov 2018 9:00 AM IST
    Bengaluru: Merck a leading science and technology company, has recently launched the Merck India Charitable Trust Scholarship (MICT) at an event where...
    Dr Reddys gets 8 observations from USFDA for Duvvada plant

    Dr Reddy's gets 8 observations from USFDA for Duvvada plant

    Medical Dialogues Bureau31 Oct 2018 5:17 PM IST
    New Delhi: Dr Reddy's Laboratories Tuesday said US health regulator has issued eight observations after inspecting its formulations plant at Duvvada,...
    Glenmark gets USFDA nod for generic Derma-Smoothe Topical Oil

    Glenmark gets USFDA nod for generic Derma-Smoothe Topical Oil

    Medical Dialogues Bureau31 Oct 2018 5:16 PM IST
    New Delhi: Glenmark Pharmaceuticals Tuesday said it has received final approval from the US health regulator for the generic version of Derma-Smoothe...
    Pfizer lowers revenue forecast on strong dollar, supply issues

    Pfizer lowers revenue forecast on strong dollar, supply issues

    Medical Dialogues Bureau31 Oct 2018 5:15 PM IST
    U.S. drugmaker Pfizer Inc cut the top end of its full-year revenue forecast range on Tuesday, citing a stronger dollar and lower revenue from its...
    PrevNext

    Popular Stories

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok